Tisagenlecleucel CAR T-cell therapy in secondary CNS lymphoma

Chimeric antigen receptor (CAR) T cells targeting CD19 have emerged as a leading engineered T-cell therapy for relapsed/refractory B-cell non-Hodgkin lymphoma. The phase 1/2 clinical trials that led to US Food and Drug Administration approval excluded patients with central nervous system (CNS) invol...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Blood
Hlavní autoři: Frigault, Matthew J., Dietrich, Jorg, Martinez-Lage, Maria, Leick, Mark, Choi, Bryan D., DeFilipp, Zachariah, Chen, Yi-Bin, Abramson, Jeremy, Crombie, Jennifer, Armand, Philippe, Nayak, Lakshmi, Panzini, Chris, Riley, Lauren S., Gallagher, Kathleen, Maus, Marcela V.
Médium: Artigo
Jazyk:Inglês
Vydáno: American Society of Hematology 2019
Témata:
Immunobiology and Immunotherapy
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7022436/
https://ncbi.nlm.nih.gov/pubmed/31320380
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood.2019001694
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky